Literature DB >> 2552904

Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.

R J Fass1, R B Prior.   

Abstract

The in vitro activities of ticarcillin, piperacillin, clavulanic acid, tazobactam, ticarcillin-clavulanate, and piperacillin-tazobactam against 819 bacterial isolates were compared. The two beta-lactamase inhibitors, clavulanic acid and tazobactam, had little useful antibacterial activity but enhanced the activities of the penicillins against beta-lactamase-producing strains of Haemophilus influenzae, Branhamella catarrhalis, and methicillin-susceptible Staphylococcus aureus; all strains were susceptible to both combinations. Both enzyme inhibitors also enhanced the activities of the penicillins against most strains of Escherichia coli, Klebsiella spp., Citrobacter diversus, Proteus spp., Providencia spp., and Bacteroides spp. and against occasional strains of Citrobacter freundii, Enterobacter spp., and Serratia marcescens. Clavulanic acid frequently enhanced the activity of ticarcillin against Xanthomonas maltophilia, and tazobactam frequently enhanced the activity of piperacillin against Morganella morganii. Enhancement was observed primarily with strains relatively resistant to the penicillins. In general, clavulanic acid was more effective than tazobactam in enhancing penicillin activity against Klebsiella spp., C. diversus, X. maltophilia, and Bacteroides spp., whereas tazobactam was more effective against Escherichia coli and Proteeae. There was little or no enhancement of activity against Enterococcus faecalis, Aeromonas hydrophila, Pseudomonas aeruginosa, Pseudomonas cepacia, or Acinetobacter anitratus. Clavulanic acid occasionally antagonized the activity of ticarcillin against ticarcillin-susceptible members of the family Enterobacteriaceae, but those strains were still considered susceptible to the combination. Tazobactam never antagonized the activity of piperacillin. In a direct comparison of the activities of ticarcillin-clavulanate and piperacillin-tazobactam, the two were equally active against H. influenzae, B. catarrhalis, and S. aureus; the latter was more active against E. faecalis. For relatively susceptible strains of members of the family Enterobacteriaceae, neither combination was predictably more active than the other, but relatively resistant strains were generally more susceptible to piperacillin-tazobactam. Piperacillin-tazobactam was more active than ticarcillin-clavulanate against A. hydrophila, P. aeruginosa, and P. cepacia, similar in activity against A. anitratus, and less active against X. maltophilia and Bacteroides spp.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2552904      PMCID: PMC172638          DOI: 10.1128/AAC.33.8.1268

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases.

Authors:  L Gutmann; M D Kitzis; S Yamabe; J F Acar
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

2.  Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests.

Authors:  C C Sanders; J P Iaconis; G P Bodey; G Samonis
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

3.  Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes.

Authors:  P C Appelbaum; M R Jacobs; S K Spangler; S Yamabe
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

4.  Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads.

Authors:  M R Jacobs; S C Aronoff; S Johenning; S Yamabe
Journal:  J Antimicrob Chemother       Date:  1986-08       Impact factor: 5.790

5.  Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.

Authors:  M R Jacobs; S C Aronoff; S Johenning; D M Shlaes; S Yamabe
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

6.  In vitro susceptibilities of four species of coagulase-negative staphylococci.

Authors:  R J Fass; V L Helsel; J Barnishan; L W Ayers
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

7.  Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.

Authors:  S C Aronoff; M R Jacobs; S Johenning; S Yamabe
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

8.  Branhamella catarrhalis: antibiotic sensitivities and beta-lactamases.

Authors:  E E Stobberingh; B I Davies; C P van Boven
Journal:  J Antimicrob Chemother       Date:  1984-01       Impact factor: 5.790

9.  National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae.

Authors:  G V Doern; J H Jorgensen; C Thornsberry; D A Preston; T Tubert; J S Redding; L A Maher
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

  9 in total
  27 in total

Review 1.  Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players.

Authors:  Young R Lee; Danni McMahan; Catherine McCall; Gregory K Perry
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

2.  Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model.

Authors:  Maria J Melchers; Anita C van Mil; Claudia Lagarde; Jan den Hartigh; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

3.  Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.

Authors:  S Gatermann; R Marre
Journal:  Infection       Date:  1991 Mar-Apr       Impact factor: 3.553

Review 4.  Current antimicrobial therapy of anaerobic infections.

Authors:  C V Sanders; K E Aldridge
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

5.  In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli.

Authors:  R J Fass; J Barnishan; M C Solomon; L W Ayers
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

6.  Relevant breakpoints for ticarcillin-clavulanic acid should be set primarily with data from ticarcillin-resistant strains.

Authors:  C C Sanders; S J Cavalieri
Journal:  J Clin Microbiol       Date:  1990-04       Impact factor: 5.948

Review 7.  Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy.

Authors:  P Charbonneau
Journal:  Intensive Care Med       Date:  1994-07       Impact factor: 17.440

8.  Susceptibility testing of Propionibacterium acnes comparing agar dilution with E test.

Authors:  M A Smith; P Alperstein; K France; E M Vellozzi; H D Isenberg
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

9.  Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  James A Karlowsky; Mellany K Weaver; Clyde Thornsberry; Michael J Dowzicky; Mark E Jones; Daniel F Sahm
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

10.  Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam.

Authors:  M A Pfaller; A L Barry; P C Fuchs; E H Gerlach; D J Hardy; J C McLaughlin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.